SURAKSHA

Suraksha Diagnostic share price & results

Suraksha Diagnostic Limited· Healthcare

Kolkata-based diagnostics chain running pathology & radiology labs, collection centres and clinics across East and North-East India.

₹353.5 +3.05%
MCap ₹1.8k Cr Price to earnings (TTM to Sept 2026) 44.88× Return on equity (TTM to Sept 2026) 14.86%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day SURAKSHA alerts.

Results to: Sept 2026 Latest analysed call: Q1 FY27 Ownership as of: Sept 2026
SURAKSHA at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

3 of 4 judged targets kept · 8 open · verdicts reflect calls analysed to Q1 FY27.

Suraksha Diagnostic Limited management guidance track record on Inve: 12 targets tracked across analysed earnings calls (3 achieved, 1 missed, 8 open).

Active guidance across Growth (1) · Operations (1).

TargetOriginal wordingSaidLatest callVerdict
Operations FY27 EBITDA Margin
around 33%
Q4 FY26
Q1 FY27:Achieved 36% in Q1. Guidance raised to 'not below 34%' for FY27.
Revised Up
Growth Total Centers Target
100 centers in the next two to three years
Q1 FY26
Q1 FY27:At 72 centers, reiterated target of 100 by FY28.
On Track

Source: Inve Guidance Tracker for Suraksha Diagnostic Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Suraksha Diagnostic Limited's 12 targets was missed. See which ones, and which are quietly gone. The 2 above are the free sample; 10 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q1 FY27 · 13 Aug 2026

Q1 FY27: Suraksha Diagnostic Limited Q1 FY27

Suraksha Diagnostic Limited reported a strong Q1 FY27, with robust revenue growth of 21% and significant PAT growth of 40%. Margin expansion was noted across both mature and newer centers, with the latter turning profitable. The genomics segment showed exceptional growth, and the company continued its network expansion strategy into new geographies while focusing on operational efficiencies.

What management highlighted

  • Revenue of INR 887 million, up 21% YoY, reflecting strong business momentum.
  • EBITDA margin expanded 200 bps to 36%, driven by volume expansion and operating leverage.
  • PAT grew significantly by 40% YoY to INR 128 million, demonstrating improved profitability.

Source: Inve analysis of Suraksha Diagnostic Limited’s Q1 FY27 earnings call · to 13 Aug 2026

Compare across 6 analysed calls

Price & Snapshot

₹353.5 +3.05% · +₹10.45

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance +14.0% 1Y

₹250₹300₹350Nov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 13 Aug 2026

1Y: ₹310.1 on 14 Nov 2025 → ₹353.5. High ₹356.45 (11 Nov 2026), low ₹227.95 (30 Mar 2026).

Previous close
₹343.05
Market cap
₹1.8k Cr
52-week range
₹227.95 – ₹356.45
One year
+17.09%
Price to earnings (TTM to Sept 2026)
44.88×
Return on equity (TTM to Sept 2026)
14.86%

Reported

Key financial metrics & valuation ratios

Revenue: 95.0 ₹ crore (+25.0% YoY) · Net profit: 15.0 ₹ crore (+66.7% YoY) · Return on equity: 14.86 % (−2.4 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue95.0 ₹ crore+25.0% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin36.0 %+5.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit15.0 ₹ crore+66.7% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity14.86 %−2.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin4.84 %−3.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)24.91 %+7.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Customers, suppliers & partners

Customers, suppliers & partner mentions

Named customers, suppliers, and partners mentioned on recent earnings calls. Click any row to read the disclosure.

Counterparties named by Suraksha Diagnostic Limited

  • Suraksha Diagnostic Limited → acquires or invests in → Fetomat

    Acquires / invests · Closed / completed · Q3 FY26
  • Suraksha Diagnostic Limited → acquires or invests in → Fetomat Wellness

    Acquires / invests · Closed / completed · Q2 FY26
  • Suraksha Diagnostic Limited → acquires or invests in → Fetomat Wellness Private Limited

    Acquires / invests · Closed / completed · Q1 FY26
  • Suraksha Diagnostic Limited → acquires or invests in → Fetomat Wellness Private Limited

    Acquires / invests · Closed / completed · Q4 FY25

Mentions over time

Q1 2025 – Q4 2025

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:SURAKSHA
Exchange
NSE
Currency
INR

What Suraksha Diagnostic Limited does

Sourced to annual report & earnings calls.

Suraksha Diagnostic operates a hub-and-spoke network of diagnostic centres, sample-collection points and laboratories offering pathology, radiology and doctor-consultation services, mostly under the Suraksha brand. It earns primarily from walk-in (B2C) patients at its own centres, supplemented by home sample collection, polyclinic consultations, hospital/corporate tie-ups, a genomics and molecular-testing vertical (Suraksha Genomics), and a fertility and pregnancy-care clinic network (Fetomat) acquired to widen its specialised-diagnostics offering. Centres are graded as large, medium or small hubs and spokes, with samples routed to a flagship central reference laboratory and satellite labs for processing.

Segments

  • Pathology
  • Radiology
  • Doctor consultancy and other services
Diagnostic centres
68
Sample collection centres
193
Laboratories (incl. 1 central reference lab + 7 satellite labs)
8
NABL-accredited labs
4
Doctors (radiologists & pathologists)
360
MRI machines
16
Founded 1992Headquarters New Town, Kolkata, West Bengal, India Company website

How the price took the results

Moved an average of ±5.2% across the last 3 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q1 FY2713 Aug 2684 13+20.0%₹270.35 → ₹304.45+12.6%
Q4 FY2622 May 2679 7+23.4%₹320.1 → ₹313.2−2.2%
Q3 FY266 Feb 2676 8+28.8%₹286 → ₹288.35+0.8%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Suraksha Diagnostic Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Suraksha Diagnostic Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Quick Answers

Frequently asked questions on Suraksha Diagnostic Limited

Compiled directly from SURAKSHA's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Suraksha Diagnostic Limited (SURAKSHA) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Suraksha Diagnostic Limited reported revenue of ₹95 Cr, net profit of ₹15 Cr, an operating margin of 36.0%. Diluted earnings per share stood at ₹2.94.

How is Suraksha Diagnostic Limited (SURAKSHA) valued today, and what growth does the stock price imply?

Suraksha Diagnostic Limited (SURAKSHA) trades at ₹353.5, with a market capitalization of ₹1.8k Cr, a trailing P/E multiple of 44.88×, return on equity (ROE) of 14.06%, ROCE of 17.35%. Reverse-DCF analysis shows the current stock price implies 27.4% annual earnings growth over the next 7 years compared with its historical net-profit CAGR of 3.0%.

Did Suraksha Diagnostic Limited (SURAKSHA) management keep or miss its earnings call guidance?

Across 12 management guidance targets tracked from Suraksha Diagnostic Limited's earnings calls, 3 were achieved, 1 missed, and 8 remain open (75% delivered among resolved targets). Sampled guidance includes FY27 EBITDA Margin: "around 33%" (stated in Q4 FY26, current status: revised up).

Who owns Suraksha Diagnostic Limited (SURAKSHA) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 49.1%, FIIs hold 14.0%, DIIs hold 21.6%, Public shareholders hold 15.4%.

What did Suraksha Diagnostic Limited (SURAKSHA) management cover on its latest concall (Q1 FY27)?

On its Q1 FY27 (Aug 2026) concall, Suraksha Diagnostic Limited reported a strong Q1 FY27, with robust revenue growth of 21% and significant PAT growth of 40%. Margin expansion was noted across both mature and newer centers, with the latter turning profitable. The genomics segment showed exceptional growth, and the company continued its network expansion strategy into new geographies while focusing on operational efficiencies. Read Suraksha Diagnostic Limited Q1 FY27 concall summary →